In 2011, two agents, ipilimumab (a fully human monoclonal antibody that blocks CTLA-4 to promote antitumor immunity) and vemurafenib (a potent inhibitor of mutated V600E BRAF) were approved in Europe and the US for the treatment of metastatic melanoma. Here, BRAF is linked to metastatic melanoma.